摘要
目的:观察评估疏肝益肾法对乳腺癌患者来曲唑治疗所致骨质疏松的临床疗效性与安全性。方法:选取绝经后乳腺癌患者48例,采用随机数字表法将其分为治疗组和对照组各24例。所有患者均口服来曲唑2.5mg,1次/d,并同时服用钙尔奇片剂1粒/d;治疗组在此基础上加服以"疏肝益肾"立法的汤药——慈菇平岩汤。分别于治疗前、治疗后对两组患者的FACT-B评分、中医症状评分、骨密度(BMD)、骨代谢指标(N-MID,CTX-I)、雌二醇水平(E2)、肿瘤标志物(CA153,CEA)进行比较,观察两组患者治疗前后各指标的变化及不良反应,并进行统计分析。结果:(1)两组患者治疗后FACT-B评分均较治疗前升高,差异有统计学意义(P<0.05);治疗组治疗后FACT-B相对应的评分均高于对照组评分,差异有统计学意义(P<0.05)。(2)治疗组治疗后相对应的中医症状评分数值较治疗前显著改善(P<0.05);对照组患者在接受治疗后相对应的中医症状评分数值与治疗前相比,差异无统计学意义(P>0.05);两组患者治疗后相对应的中医症状评分数值组间比较,治疗组相应评分显著优于对照组(P<0.05),表明治疗组患者较对照组在改善相应的中医症状方面效果更优。(3)对照组在治疗后的骨代谢指标水平较前增加(P<0.05),且骨密度值较前降低(P<0.05);治疗组治疗后的骨代谢指标水平亦有所增加(P<0.05),但骨密度并无显著降低,即患者治疗前后相应指标差异无统计学意义(P>0.05);两组患者治疗后相对应的组间骨密度数值差异无统计学意义(P>0.05)。(4)两组患者治疗前E2水平比较,差异无统计学意义(P>0.05),两组患者接受相应治疗后,其E2数值无显著改变,与治疗前相应数值比较及组间相应数值对比,其两者对应的差异均无统计学意义(P>0.05)。(5)两组患者经治疗后肿瘤标志物(CA153、CEA)均较前下降(P<0.05),且两组患者治疗前后相对应指标数值的组间对比,差异无
Objective:To observe and evaluate the clinical efficacy and safety of soothing the liver and tonifying the kidney method on osteoporosis caused by letrozole in breast cancer.Methods:48 postmenopausal breast cancer patients who visited the oncology department of Qinhuangdao Hospital of traditional Chinese medicine from September 2019 to February 2020 were selected.48 postmenopausal breast cancer patients treated with letrozole were random divided into treatment group and control group,24 cases in treatment group and 24 cases in control group.All patients were given letrozole 2.5 mg,once a day,and Caltrate tablets were taken at the same time.On this basis,the treatment group was additionally given Cigu Pingyan decoction,which was prescribed by“soothing the liver and tonifying the kidney”.Before and after treatment,the FACT-B score,TCM symptom score,bone mineral density(BMD),bone metabolism index(N-MID,CTX-I),estradiol level(E2),tumor markers(CA153,CEA)were compared between the two groups before and after treatment,and the changes and adverse reactions of the two groups were observed and analyzed statistically.Results:(1)After treatment,the FACT-B score of the two groups was higher than that before treatment,the difference was statistically significant(P<0.05);after treatment,the FACT-B score of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).(2)After treatment,the corresponding TCM symptom score of the treatment group was significantly improved compared with that before treatment(P<0.05);the corresponding TCM symptom score value of the control group after treatment was compared with that before treatment,and the corresponding difference was not statistically significant(P>0.05);the corresponding TCM symptom score value of the two groups after treatment was compared between the two groups,that is,the corresponding score of the treatment group The value was significantly better than that of the control group(P<0.05),indicating that the treatme
作者
何芸
洪月光
王振东
张毅鹏
汪旻琦
王成
He Yun;Hong Yueguang;Wang Zhendong;Zhang Yipeng;Wang Minqi;Wang Cheng(Hebei North University,Zhangjiakou 075000,China;Department of Oncology,Qinhuangdao Traditional Chinese Medicine Hospital,Qinhuangdao 066000,China;Hebei College of Traditional Chinese Medicine,Shijiazhuang 050011,China)
出处
《亚太传统医药》
2021年第9期74-78,共5页
Asia-Pacific Traditional Medicine
基金
河北省中医药管理局科研计划(2019529)
关键词
疏肝益肾法
慈菇平岩汤
乳腺癌
来曲唑
骨质疏松
Soothing the Liver and Tonifying the Kidney
Cigu Pingyan Decoction
Breast Cancer
Letrozole
Osteoporosis
